International oncology, microbiome and drug discovery expertise synergize to guide unique early cancer detection startup SAN DIEGO, Dec. 9, 2020 /PRNewswire/ -- Micronoma, the first cancer detection biotech company that uses signals from the tumor-related microbiome to diagnose cancer at an early stage with minimally-invasive liquid biopsy technology, today announced the formation of its scientific advisory board (SAB). The SAB is composed of industry experts and key opinion leaders for...

Innovative early cancer detection company establishes headquarters and adds three key executive positions San Diego, Calif. (November 5, 2020). Micronoma, an early-stage cancer detection biotech company seeking to develop and commercialize a minimally-invasive, unique...

Biotech maven joins early-stage cancer detection company utilizing innovative microbiome analysis SAN DIEGO, Sept. 30, 2020 /PRNewswire/ -- Micronoma, an early stage cancer-detection start-up seeking to develop and commercialize a minimally-invasive, unique...

For Immediate Release Media Contact: Celia Sepulveda, Celia.Sepulveda@Micronoma.com, 858.337.1326   Micronoma Launches with $3 Million Seed Funding   First early cancer-detection company to use microbial biomarkers in diagnostics   San Diego, Calif....

From a simple blood draw, microbial DNA may reveal who has cancer and which type, even at early stages When Gregory Poore was a freshman in college, his otherwise healthy grandmother was shocked to learn that she had late-stage pancreatic cancer. The condition was...

Microbiome analyses of blood and tissues suggest cancer diagnostic approach.
Systematic characterization of the cancer microbiome provides the opportunity to develop techniques that exploit non-human, microorganism-derived molecules in the diagnosis of a major human disease.

Micronoma will be presenting at Biocom this year. Go to Biocom Micronoma San Diego, CA, USA info@micronoma.comlinkedin